Galectin Therapeutics Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 3.52 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 354.99M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company’s lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Details
| Name | Galectin Therapeutics Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 9 |
| Founded | 2000 |
| Ceo | Joel Lewis |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US3632252025 |
| Cusip | 363225202 |
| Cik | 0001133416 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Khurram Jamil M.D. | Chief Medical Officer |
| Robert Tritt J.D. | General Counsel |
| Jim Wilkins Ph.D. | Head of CMC and Pharmaceutical Development |
| Beth Knowles | Executive Assistant and Officer Manager |
Contact
| Address | 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, Georgia 30071, United States |
| Phone | 678 620 3186 |
| Website | https://galectintherapeutics.com |